Published in Proteome Sci on June 28, 2011
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III. Oncol Lett (2014) 0.80
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Prediction of spontaneous regression of cervical intraepithelial neoplasia lesions grades 2 and 3 by proteomic analysis. Int J Proteomics (2014) 0.77
Does CIN2 Have the Same Aggressive Potential As CIN3? A Secondary Analysis of High-Grade Cytology Recurrence in Women Treated with Cold-Coagulation Cervical Treatment. Geburtshilfe Frauenheilkd (2017) 0.75
Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol (2001) 28.01
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet (2006) 5.65
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell (2008) 5.38
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
The human keratins: biology and pathology. Histochem Cell Biol (2008) 5.13
Keratin expression in human tissues and neoplasms. Histopathology (2002) 4.91
Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol (1993) 4.67
Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA (2004) 2.26
Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J (1997) 2.21
Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3. Aust N Z J Obstet Gynaecol (2010) 2.09
Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol (2010) 1.73
Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev (2003) 1.72
Clinical utility of cytokeratins as tumor markers. Clin Biochem (2004) 1.63
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 1.57
Keratins and skin disorders. J Pathol (2004) 1.48
Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res (2007) 1.46
Lamin A/C is a risk biomarker in colorectal cancer. PLoS One (2008) 1.37
Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev (2006) 1.36
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol (2007) 1.22
The continuing evolution of shotgun proteomics. Drug Discov Today (2005) 1.12
Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol (2002) 1.11
Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation. Exp Cell Res (1992) 1.11
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol (2004) 1.10
Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci (2009) 1.10
Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev (2010) 1.08
Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine (2001) 1.04
Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol (2007) 1.01
Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol (2005) 1.00
Suprabasal marker proteins distinguishing keratinizing squamous epithelia: cytokeratin 2 polypeptides of oral masticatory epithelium and epidermis are different. Differentiation (1992) 0.99
Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem (2008) 0.93
Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope (2009) 0.91
Diagnostic protein marker patterns in squamous cervical cancer. Proteomics Clin Appl (2009) 0.89
Differential tissue-specific protein markers of vaginal carcinoma. Br J Cancer (2009) 0.86
Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Methods Mol Med (2005) 0.83
Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci (2009) 0.78
Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res (2003) 4.22
Reflectance spectroscopy for in vivo detection of cervical precancer. J Biomed Opt (2002) 2.10
Light scattering from cervical cells throughout neoplastic progression: influence of nuclear morphology, DNA content, and chromatin texture. J Biomed Opt (2003) 1.96
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Near real-time confocal microscopy of amelanotic tissue: detection of dysplasia in ex vivo cervical tissue. Acad Radiol (2002) 1.84
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol (2006) 1.79
Microanatomical and biochemical origins of normal and precancerous cervical autofluorescence using laser-scanning fluorescence confocal microscopy. Photochem Photobiol (2003) 1.69
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology (2012) 1.64
Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol (2009) 1.62
Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61
Quantitative histopathological analysis of cervical intra-epithelial neoplasia sections: methodological issues. Cell Oncol (2004) 1.58
Combined reflectance and fluorescence spectroscopy for in vivo detection of cervical pre-cancer. J Biomed Opt (2005) 1.56
Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol (2006) 1.52
Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol (2005) 1.49
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Improved lymph node harvest from resected colon cancer specimens did not cause upstaging from TNM stage II to III. World J Surg (2011) 1.47
Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol (2010) 1.47
Subvisual chromatin changes in cervical epithelium measured by texture image analysis and correlated with HPV. Gynecol Oncol (2005) 1.47
Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol (2004) 1.46
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol (2010) 1.46
An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol (2005) 1.43
Optimal excitation wavelengths for discrimination of cervical neoplasia. IEEE Trans Biomed Eng (2002) 1.42
Lymphangioma circumscriptum of the vulva: a review of the literature. Obstet Gynecol (2003) 1.38
Undifferentiated carcinoma of the endometrium: a review. Pathology (2007) 1.38
Primary retroperitoneal mucinous tumors: a clinicopathologic study of 18 cases. Am J Surg Pathol (2009) 1.36
Sources of scattering in cervical tissue: determination of the scattering coefficient by confocal microscopy. Appl Opt (2005) 1.35
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer (2011) 1.33
Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol (2004) 1.32
Undifferentiated carcinoma of the endometrium. Am J Surg Pathol (2005) 1.30
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol (2003) 1.29
Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol Pathol (2003) 1.28
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer (2006) 1.25
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol (2007) 1.24
Real-time reflectance confocal microscopy: comparison of two-dimensional images and three-dimensional image stacks for detection of cervical precancer. J Biomed Opt (2007) 1.23
Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol (2007) 1.23
Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol (2004) 1.22
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol (2004) 1.22
Fiber optic confocal reflectance microscopy: a new real-time technique to view nuclear morphology in cervical squamous epithelium in vivo. Opt Express (2003) 1.21
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol (2013) 1.19
Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary. Am J Surg Pathol (2007) 1.17
Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol (2004) 1.17
Light scattering from normal and dysplastic cervical cells at different epithelial depths: finite-difference time-domain modeling with a perfectly matched layer boundary condition. J Biomed Opt (2003) 1.15
Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol (2004) 1.14
Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol (2007) 1.13
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat (2008) 1.12
Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol (2003) 1.12
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer (2003) 1.12
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol (2009) 1.08
Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer. Gynecol Oncol (2009) 1.07
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol (2007) 1.06
Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol (2007) 1.05
Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol (2008) 1.05
Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol (2006) 1.05
Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol (2009) 1.04
Exploratory analysis of quantitative histopathology of cervical intraepithelial neoplasia: objectivity, reproducibility, malignancy-associated changes, and human papillomavirus. Cytometry A (2004) 1.04
Conservative management of a uterine tumor resembling an ovarian sex cord-stromal tumor. Gynecol Oncol (2004) 1.04
Low-grade serous primary peritoneal carcinoma. Gynecol Oncol (2011) 1.03
Benign peritoneal cystic mesothelioma. World J Surg (2006) 1.03
Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol (2002) 1.03
Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol (2010) 1.03
Relationship between collagen autofluorescence of the human cervix and menopausal status. Photochem Photobiol (2003) 1.03
Endometrial endometrioid adenocarcinoma in a premenopausal woman presenting with metastasis to bone: a case report and review of the literature. Int J Gynecol Pathol (2002) 1.02
Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol (2002) 1.02
Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol (2009) 1.01
Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia: Testing a device as an adjunct to colposcopy. Int J Cancer (2010) 1.00
Uterine tumors with neuroectodermal differentiation: a series of 17 cases and review of the literature. Am J Surg Pathol (2008) 1.00
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol (2003) 1.00
Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol (2002) 1.00
Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol (2011) 0.99
[Appendiceal mucinous cystadenoma]. Tidsskr Nor Laegeforen (2005) 0.99
Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions. Cancer (2006) 0.99
Temperature and nitrogen effects on regulators and products of the flavonoid pathway: experimental and kinetic model studies. Plant Cell Environ (2008) 0.99
Endometrioid stromal sarcoma: a clinicopathologic study of 63 cases. Am J Surg Pathol (2013) 0.98
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol (2011) 0.98
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol (2011) 0.98
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol (2011) 0.97
The significance of neuroendocrine expression in undifferentiated carcinoma of the endometrium. Int J Gynecol Pathol (2009) 0.96
Serum 25(OH)D is a 2-year predictor of all-cause mortality, cardiac death and sudden cardiac death in chest pain patients from Northern Argentina. PLoS One (2012) 0.96
Automated image analysis of digital colposcopy for the detection of cervical neoplasia. J Biomed Opt (2008) 0.96
Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta (2012) 0.96
Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary. Ann Diagn Pathol (2003) 0.96
Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res (2005) 0.95
The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol (2004) 0.95
Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest (2003) 0.95
Multispectral digital colposcopy for in vivo detection of cervical cancer. Opt Express (2003) 0.94
Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol (2010) 0.93
Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat (2008) 0.93
Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. Am J Surg Pathol (2008) 0.93
Metastatic tumors of the vulva: a clinicopathologic study of 66 cases. Am J Surg Pathol (2003) 0.92
Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases. Am J Surg Pathol (2006) 0.92
Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med (2013) 0.91
Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol (2010) 0.91